This Drug Maker Says Its Tech Delivers 3,500X The Amount Of Anti-Cancer Medicine Into The Tumor Compared To Traditional Chemo Methods


27% profits every 20 days?

This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.


Michael Gareau, Chairman of the Board, Founding President & CEO of Starpax Biopharma Inc., was recently interviewed by Benzinga.

Starpax is a biopharma and medtech company that has developed a revolutionary platform for treating cancer. The company has developed what it calls Magnetodrones which deliver cancer drugs directly into a tumor. They are self-propelled and do not need to enter the bloodstream. They work in tandem with the Polartrak, a device that keeps the Magnetodrones contained within the tumor.

The company is currently making preparations to begin clinical trials in humans.

Learn more here:

Featured photo by National Cancer Institute on Unsplash.

This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice.


27% profits every 20 days?

This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.


ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!

Posted In: BiotechInterviewGeneralStarpax Biopharma